BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

11596

531633

LINCOLN

img img img img
No Data Available

LINCOLN PHARMA LTD performance

Today’s low

Today’s high

₹ 511.00 ₹ 520.35
₹ 515.75

52 week low

52 week high

₹ 490.00 ₹ 979.50
₹ 515.75

Open Price

₹ 519.70

Prev. Close

₹ 516.15

Volume (Shares)

16060.00

Total traded value

₹ 82.82

Upper Circuit

₹ 619.35

Lower Circuit

₹ 412.95

info

LINCOLN PHARMA LTD Share Price Update

As of the latest trading session, LINCOLN PHARMA LTD share price is currently at ₹ 513.6, which is down by ₹ -2.55 from its previous closing. Today, the stock has fluctuated between ₹ 511.00 and ₹ 520.35. Over the past year, LINCOLN PHARMA LTD has achieved a return of -17.86 %. In the last month alone, the return has been -1.96 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

LINCOLN PHARMA LTD fundamentals


  • Market cap (Cr)

    1,033.00

  • P/E Ratio (TTM)

    12.93

  • Beta

    1.17

  • Book Value / share

    357.35

  • Return on equity

    13.02%

  • EPS (TTM)

    39.94

  • Dividend yield

    0.35%

  • Net profit/quarter (Cr)

    19.98

info icon alternate text
  • Market cap (Cr)

    1,024.80

  • P/E Ratio (TTM)

    12.93

  • Beta

    1.16

  • Book Value / share

    357.35

  • Return on equity

    13.02%

  • EPS (TTM)

    39.94

  • Dividend yield

    0.35%

  • Net profit/quarter (Cr)

    19.98

info icon alternate text

LINCOLN PHARMA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 163.36
Operating Expense 141.78
Net Profit 19.98
Net Profit Margin (%) 12.23
Earnings Per Share (EPS) 9.98
EBITDA 32.66
Effective Tax Rate (%) 30.64
Particulars JUN 2025 (Values in Cr)
Revenue 154.07
Operating Expense 133.95
Net Profit 27.68
Net Profit Margin (%) 17.96
Earnings Per Share (EPS) 13.82
EBITDA 39.08
Effective Tax Rate (%) 21.78
Particulars MAR 2025 (Values in Cr)
Revenue 168.18
Operating Expense 145.06
Net Profit 11.58
Net Profit Margin (%) 6.88
Earnings Per Share (EPS) 5.78
EBITDA 19.85
Effective Tax Rate (%) 28.73
Particulars DEC 2024 (Values in Cr)
Revenue 146.55
Operating Expense 126.84
Net Profit 20.77
Net Profit Margin (%) 14.17
Earnings Per Share (EPS) 10.37
EBITDA 32.63
Effective Tax Rate (%) 27.58
Particulars SEP 2024 (Values in Cr)
Revenue 161.21
Operating Expense 136.41
Net Profit 26.33
Net Profit Margin (%) 16.33
Earnings Per Share (EPS) 13.15
EBITDA 38.35
Effective Tax Rate (%) 24.29
Particulars MAR 2025 (Values in Cr)
Revenue 623.23
Operating Expense 536.52
Net Profit 82.35
Net Profit Margin (%) 13.21
Earnings Per Share (EPS) 41.11
EBITDA 123.97
Effective Tax Rate (%) 24.58
Particulars MAR 2024 (Values in Cr)
Revenue 580.55
Operating Expense 492.72
Net Profit 93.30
Net Profit Margin (%) 16.07
Earnings Per Share (EPS) 46.58
EBITDA 134.32
Effective Tax Rate (%) 23.67
Particulars MAR 2023 (Values in Cr)
Revenue 510.31
Operating Expense 432.34
Net Profit 72.90
Net Profit Margin (%) 14.28
Earnings Per Share (EPS) 36.40
EBITDA 111.66
Effective Tax Rate (%) 27.43
Particulars MAR 2022 (Values in Cr)
Revenue 472.08
Operating Expense 386.15
Net Profit 69.36
Net Profit Margin (%) 14.69
Earnings Per Share (EPS) 34.63
EBITDA 105.47
Effective Tax Rate (%) 27.69
Particulars MAR 2021 (Values in Cr)
Revenue 422.91
Operating Expense 344.98
Net Profit 62.25
Net Profit Margin (%) 14.71
Earnings Per Share (EPS) 31.08
EBITDA 92.78
Effective Tax Rate (%) 25.60
Particulars MAR 2025 (Values in Cr)
Book Value / Share 335.34
ROE % 13.02
ROCE % 17.42
Total Debt to Total Equity 0.00
EBITDA Margin 19.89
Particulars MAR 2024 (Values in Cr)
Book Value / Share 295.98
ROE % 17.04
ROCE % 22.35
Total Debt to Total Equity 0.00
EBITDA Margin 23.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 250.86
ROE % 15.59
ROCE % 21.61
Total Debt to Total Equity 0.00
EBITDA Margin 21.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 216.12
ROE % 17.36
ROCE % 24.03
Total Debt to Total Equity 0.00
EBITDA Margin 22.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share 182.92
ROE % 18.32
ROCE % 24.60
Total Debt to Total Equity 0.01
EBITDA Margin 21.89
Particulars MAR 2025 (Values in Cr)
Book Value / Share 335.34
ROE % 13.02
ROCE % 17.42
Total Debt to Total Equity 0.00
EBITDA Margin 19.89
Particulars MAR 2024 (Values in Cr)
Book Value / Share 295.98
ROE % 17.04
ROCE % 22.35
Total Debt to Total Equity 0.00
EBITDA Margin 23.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 250.86
ROE % 15.59
ROCE % 21.60
Total Debt to Total Equity 0.00
EBITDA Margin 21.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 216.12
ROE % 17.35
ROCE % 24.02
Total Debt to Total Equity 0.00
EBITDA Margin 22.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share 182.92
ROE % 18.56
ROCE % 24.90
Total Debt to Total Equity 0.01
EBITDA Margin 21.94
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 22.43
Total Assets 797.00
Total Liabilities 797.00
Total Equity 671.66
Share Outstanding 20029728
Price to Book Ratio 1.64
Return on Assets (%) 10.33
Return on Capital (%) 12.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.83
Total Assets 700.29
Total Liabilities 700.29
Total Equity 592.83
Share Outstanding 20029728
Price to Book Ratio 1.98
Return on Assets (%) 13.32
Return on Capital (%) 15.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 34.31
Total Assets 587.42
Total Liabilities 587.42
Total Equity 502.47
Share Outstanding 20029728
Price to Book Ratio 1.35
Return on Assets (%) 12.41
Return on Capital (%) 14.45
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 18.79
Total Assets 534.35
Total Liabilities 534.35
Total Equity 432.87
Share Outstanding 20029728
Price to Book Ratio 1.44
Return on Assets (%) 12.97
Return on Capital (%) 15.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 13.84
Total Assets 452.35
Total Liabilities 452.35
Total Equity 366.39
Share Outstanding 20029728
Price to Book Ratio 1.23
Return on Assets (%) 13.76
Return on Capital (%) 16.97
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 21.99
Total Assets 796.86
Total Liabilities 796.86
Total Equity 671.66
Share Outstanding 20029728
Price to Book Ratio 1.64
Return on Assets (%) 10.33
Return on Capital (%) 12.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.38
Total Assets 700.14
Total Liabilities 700.14
Total Equity 592.83
Share Outstanding 20029728
Price to Book Ratio 1.98
Return on Assets (%) 13.32
Return on Capital (%) 15.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 33.84
Total Assets 587.25
Total Liabilities 587.25
Total Equity 502.47
Share Outstanding 20029728
Price to Book Ratio 1.35
Return on Assets (%) 12.41
Return on Capital (%) 14.45
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 18.43
Total Assets 534.11
Total Liabilities 534.11
Total Equity 432.87
Share Outstanding 20029728
Price to Book Ratio 1.44
Return on Assets (%) 12.98
Return on Capital (%) 15.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 13.43
Total Assets 451.80
Total Liabilities 451.80
Total Equity 366.39
Share Outstanding 20029728
Price to Book Ratio 1.23
Return on Assets (%) 13.77
Return on Capital (%) 16.97
Particulars MAR 2025 (Values in Cr)
Net Income 109.18
Cash from Operations 119.32
Cash from Investing -78.94
Cash from Financing -6.40
Net change in Cash 7.66
Free Cash Flow 138.35
Particulars MAR 2024 (Values in Cr)
Net Income 122.24
Cash from Operations 89.36
Cash from Investing -57.34
Cash from Financing -5.18
Net change in Cash 0.69
Free Cash Flow 128.84
Particulars MAR 2023 (Values in Cr)
Net Income 100.47
Cash from Operations 68.87
Cash from Investing -36.64
Cash from Financing -4.50
Net change in Cash -1.88
Free Cash Flow 83.13
Particulars MAR 2022 (Values in Cr)
Net Income 95.93
Cash from Operations 99.82
Cash from Investing -78.08
Cash from Financing -2.55
Net change in Cash -4.50
Free Cash Flow 145.35
Particulars MAR 2021 (Values in Cr)
Net Income 83.72
Cash from Operations 88.76
Cash from Investing -64.22
Cash from Financing -5.74
Net change in Cash -0.70
Free Cash Flow 97.51
Particulars MAR 2025 (Values in Cr)
Net Income 109.18
Cash from Operations 119.32
Cash from Investing -78.94
Cash from Financing -6.40
Net change in Cash 7.66
Free Cash Flow 138.35
Particulars MAR 2024 (Values in Cr)
Net Income 122.24
Cash from Operations 89.37
Cash from Investing -57.34
Cash from Financing -5.17
Net change in Cash 0.72
Free Cash Flow 128.84
Particulars MAR 2023 (Values in Cr)
Net Income 100.45
Cash from Operations 68.76
Cash from Investing -36.64
Cash from Financing -4.50
Net change in Cash -1.98
Free Cash Flow 83.02
Particulars MAR 2022 (Values in Cr)
Net Income 95.92
Cash from Operations 99.82
Cash from Investing -78.08
Cash from Financing -2.56
Net change in Cash -4.46
Free Cash Flow 145.34
Particulars MAR 2021 (Values in Cr)
Net Income 83.67
Cash from Operations 88.84
Cash from Investing -64.39
Cash from Financing -5.73
Net change in Cash -0.74
Free Cash Flow 97.59
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 29.00 14.22 1.50 222.24 28.35 / 68.00
BLISS GVS PHARMA LTD 166.85 16.09 1.55 1763.98 105.05 / 190.65
CIPLA LTD 1523.45 22.62 3.73 123059.91 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 284.80 7.48 2.14 838.19 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 29.00 23.58 4.04 222.24 28.35 / 68.00
AMRUTAJAN HEALTH LTD 684.65 34.91 5.78 1979.37 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9049.60 97.87 28.31 22624.00 6301.00 / 10653.05
BLISS GVS PHARMA LTD 166.85 22.52 1.59 1763.98 105.05 / 190.65

LINCOLN PHARMA LTD shareholding pattern

Holding

45.48%
49.77%
4.72%
0.01%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

LINCOLN PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
515.75 -0.07 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 521.90
  • 26 Days 526.90
  • 10 Days 524.30
  • 50 Days 531.50
  • 12 Days 524.70
  • 100 Days 543.00
  • 20 Days 525.90
  • 200 Days 568.70
517.68 PIVOT

First Support

513.02

First Resistance

520.82

Second Support

509.88

Second Resistance

525.48

Third Support

505.22

Third Resistance

528.62

RSI

41.80

ADX

20.12

MACD

-2.17

Williams % R

-50.57

Commodity Channel Index (CCI)

-107.62

Date

2025-11-26

Week

10191.00

Same Day

10946.00

Month

14557.00

1 Year

1.18

3 Year

0.91

Over 1 Month

-1.96%

down

Over 1 Year

-17.86%

down

Over 3 Months

-4.74%

down

Over 3 Years

16.61%

down

Over 6 Months

-7.78%

down

Over 5 Years

16.47%

down

LINCOLN PHARMA LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2025 1.8 Final 12 Sep 2025 Equity shares
13 Sep 2024 1.8 Final 14 Sep 2024 Equity shares
15 Sep 2023 1.5 Final 16 Sep 2023 Equity shares
15 Sep 2022 1.5 Final 17 Sep 2022 Equity shares
16 Sep 2021 1.5 Final 18 Sep 2021 Equity shares
05 Mar 2020 1.5 Interim 06 Mar 2020 Equity shares
19 Sep 2019 1.5 Final 21 Sep 2019 Equity shares
19 Sep 2018 1.5 Final 22 Sep 2018 Equity shares
21 Sep 2017 1.2 Final 23 Sep 2017 Equity shares
23 Sep 2016 1.0 Final 27 Sep 2016 Equity shares
23 Sep 2015 1.0 Final 26 Sep 2015 Equity shares
25 Sep 2014 0.6 Final 27 Sep 2014 Equity shares
19 Sep 2013 0.6 Final 21 Sep 2013 Equity shares
20 Sep 2012 0.6 Final 22 Sep 2012 Equity shares
22 Sep 2011 0.6 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.2 Final 25 Sep 2010 Equity shares
17 Sep 2009 1.2 Final 19 Sep 2009 Equity shares
18 Sep 2008 0.24 Final 20 Sep 2008 Equity shares
20 Sep 2007 0.24 Final 22 Sep 2007 Equity shares
14 Sep 2006 0.0 Final 16 Sep 2006 Equity shares
25 Aug 2005 0.0 Final 29 Aug 2005 Equity shares
Ex-Date Old FV NEW FV Record Date
19 Mar 2009 2.0 10.0 26 Mar 2009
08 Feb 2006 10.0 2.0 16 Feb 2006
Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2025 1.8 Final 12 Sep 2025 Equity shares
13 Sep 2024 1.8 Final 14 Sep 2024 Equity shares
15 Sep 2023 1.5 Final 16 Sep 2023 Equity shares
15 Sep 2022 1.5 Final 17 Sep 2022 Equity shares
16 Sep 2021 1.5 Final 18 Sep 2021 Equity shares
05 Mar 2020 1.5 Interim 06 Mar 2020 Equity shares
19 Sep 2019 1.5 Final 21 Sep 2019 Equity shares
19 Sep 2018 1.5 Final 22 Sep 2018 Equity shares
21 Sep 2017 1.2 Final 23 Sep 2017 Equity shares
23 Sep 2016 1.0 Final 27 Sep 2016 Equity shares
23 Sep 2015 1.0 Final 26 Sep 2015 Equity shares
25 Sep 2014 0.6 Final 27 Sep 2014 Equity shares
19 Sep 2013 0.6 Final 21 Sep 2013 Equity shares
20 Sep 2012 0.6 Final 22 Sep 2012 Equity shares
22 Sep 2011 0.6 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.2 Final 25 Sep 2010 Equity shares
17 Sep 2009 1.2 Final 19 Sep 2009 Equity shares
18 Sep 2008 0.24 Final 20 Sep 2008 Equity shares
20 Sep 2007 0.24 Final 22 Sep 2007 Equity shares
14 Sep 2006 0.0 Final 16 Sep 2006 Equity shares
25 Aug 2005 0.0 Final 29 Aug 2005 Equity shares
Ex-Date Old FV NEW FV Record Date
19 Mar 2009 2.0 10.0 26 Mar 2009
08 Feb 2006 10.0 2.0 16 Feb 2006

LINCOLN PHARMA LTD Share Price

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others.

The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.

The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.'96 to part-finance its project.

The Company launched Next Generation Progesterone Therapy 'ProlinSpray' during the year 2018.

During the year 2021-22, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company.

The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022. The Company commenced commercial production in Mehsana in FY 2025.

Parent organization Indian Private
NSE symbol LINCOLN
Founded 1995
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Lincoln Pharmaceuticals Ltd?

Answer Field

Lincoln Pharmaceuticals Ltd share price is for NSE ₹ 513.60 & for BSE ₹ 510.15 as on Nov 27 2025 03:29 PM.

What is the Market Cap of Lincoln Pharmaceuticals Ltd Share?

Answer Field

The market cap of Lincoln Pharmaceuticals Ltd for NSE ₹ 1,028.72 & for BSE ₹ 1,021.81 as on Nov 27 2025 03:29 PM.

What is the 52 Week High and Low of Lincoln Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Lincoln Pharmaceuticals Ltd for NSE is ₹ 979.50 and ₹ 490.00 and for BSE is ₹ 975.00 and ₹ 491.00.

What is 1 year return for Lincoln Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -17.86%.

What is the P/E Ratio of Lincoln Pharmaceuticals Ltd Share?

Answer Field

As on Nov 27 2025 03:29 PM the price-to-earnings (PE) ratio for Lincoln Pharmaceuticals Ltd share is 12.93.

What is the PB ratio of Lincoln Pharmaceuticals Ltd Share?

Answer Field

As on Nov 27 2025 03:29 PM, the price-to-book (PB) ratio for Lincoln Pharmaceuticals Ltd share is 357.35.

How to Buy Lincoln Pharmaceuticals Ltd Share?

Answer Field

You can trade in Lincoln Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Lincoln Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Lincoln Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Lincoln Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59